(-0.02%) 5 477.25 points
(-0.05%) 38 797 points
(0.03%) 19 926 points
(0.25%) $80.53
(1.26%) $2.82
(0.14%) $2 332.30
(-0.29%) $29.31
(-0.24%) $968.60
(0.02%) $0.932
(-0.14%) $10.64
(0.06%) $0.788
(-1.86%) $86.80
@ $62.06
Išleistas: 17 birž. 2024 @ 18:45
Grąža: 1.02%
Ankstesnis signalas: birž. 17 - 16:30
Ankstesnis signalas:
Grąža: 0.45 %
Live Chart Being Loaded With Signals
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally...
Stats | |
---|---|
Šios dienos apimtis | 5.61M |
Vidutinė apimtis | 3.04M |
Rinkos kapitalizacija | 14.10B |
EPS | $0.760 ( Q1 | 2024-04-30 ) |
Kita pelno data | ( $1.140 ) 2024-08-06 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E |
19.00 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $1.139 (1.82%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-06-12 | Baker Bros. Advisors Lp | Buy | 2 830 | Common Stock |
2024-06-12 | Baker Bros. Advisors Lp | Sell | 5 283 206 | Common Stock |
2024-06-12 | Baker Bros. Advisors Lp | Buy | 2 830 | Common Stock |
2024-06-12 | Baker Bros. Advisors Lp | Sell | 175 977 | Common Stock |
2024-06-12 | Baker Bros. Advisors Lp | Buy | 12 517 | Non- Qualified Stock Options (right to buy) |
INSIDER POWER |
---|
-77.51 |
Last 98 transactions |
Buy: 962 698 | Sell: 5 597 088 |
Tūris Koreliacija
Incyte Corp Koreliacija
10 Labiausiai teigiamai susiję koreliacijos | |
---|---|
ADPT | 0.947 |
NDLS | 0.938 |
NEOG | 0.928 |
RNW | 0.928 |
BIGC | 0.926 |
CWCO | 0.924 |
DCFC | 0.923 |
MAXN | 0.923 |
CLNE | 0.922 |
NVTS | 0.922 |
10 Labiausiai neigiamai susiję koreliacijos | |
---|---|
SWAV | -0.903 |
TAYD | -0.895 |
IVCB | -0.887 |
BCSA | -0.887 |
FTGC | -0.883 |
JVA | -0.882 |
KINS | -0.88 |
MTEK | -0.873 |
EML | -0.871 |
LPCN | -0.869 |
Ar žinojote?
Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).
Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.
Incyte Corp Koreliacija - Valiuta/Žaliavos
Incyte Corp Finansinės ataskaitos
Annual | 2023 |
Pajamos: | $3.70B |
Bruto pelnas: | $3.44B (93.10 %) |
EPS: | $2.67 |
FY | 2023 |
Pajamos: | $3.70B |
Bruto pelnas: | $3.44B (93.10 %) |
EPS: | $2.67 |
FY | 2022 |
Pajamos: | $3.39B |
Bruto pelnas: | $3.19B (93.90 %) |
EPS: | $1.530 |
FY | 2021 |
Pajamos: | $2.99B |
Bruto pelnas: | $2.84B (94.94 %) |
EPS: | $4.30 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Incyte Corp
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include ruxolitinib, a steroid-refractory chronic graft-versus-host-diseases (GVHD); itacitinib, which is in Phase II/III clinical trial to treat naïve chronic GVHD; and pemigatinib for treating bladder cancer, cholangiocarcinoma, myeloproliferative syndrome, and tumor agnostic. In addition, the company engages in developing Parsaclisib, which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. Additionally, it develops Retifanlimab that is in Phase II clinical trials for MSI-high endometrial cancer, merkel cell carcinoma, and anal cancer, as well as in Phase II clinical trials for patients with non-small cell lung cancer. It has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Calithera Biosciences, Inc; MacroGenics, Inc.; Merus N.V.; Syros Pharmaceuticals, Inc.; Innovent Biologics, Inc.; Zai Lab Limited; Cellenkos, Inc.; and Nimble Therapeutics, as well as clinical collaborations with MorphoSys AG and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was incorporated in 1991 and is headquartered in Wilmington, Delaware.
Apie Signalai gyvai
Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.
Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.